



**Pressrelease**

## **Report from Orexo AB's extraordinary general meeting, 19 May 2020**

Today on 19 May 2020, Orexo AB (publ) held an extraordinary general meeting. The extraordinary general meeting passed the following resolutions.

### **Long-term incentive program LTIP 2020**

The extraordinary general meeting resolved, in accordance with the board's proposal, to adopt a long-term incentive program for senior executives and key employees within the Orexo group.

### **Long-term incentive program LTIP Stay-on 2020**

The extraordinary general meeting resolved, in accordance with the board's proposal, to adopt a long-term incentive program for certain Global Management Team employees and US Leadership Team employees within the Orexo group.

Complete proposals regarding the resolutions by the extraordinary general meeting in accordance with the above are available at Orexo's website, [www.orexo.com](http://www.orexo.com).

For more information please contact [ir@orexo.com](mailto:ir@orexo.com)

### **About Orexo**

Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs mainly within the growing space of addiction. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product Zubsolv® for treatment of opioid use disorder. Total net sales for 2019 amounted to SEK 845 million and the number of employees was 127. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.

For more information about Orexo please visit, [www.orexo.com](http://www.orexo.com). You can also follow Orexo on Twitter, [@orexoabpubl](https://twitter.com/orexoabpubl), LinkedIn and YouTube.